Blood filter may tame deadly inflammation after heart attack

NCT ID NCT07687017

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether filtering a specific inflammatory protein (C-reactive protein, or CRP) from the blood can improve outcomes in people with cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood—after a heart attack. About 50 participants will receive either standard care alone or standard care plus CRP apheresis using the PentraSorb®-CRP system. The study measures changes in a risk score based on four biomarkers to see if the treatment reduces inflammation and organ damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Selective C-reactive protein apheresis (PentraSorb®-CRP)
What this could lead to
If it works, this could point toward a new way to reduce inflammation and improve survival in people with cardiogenic shock after a heart attack.
What could go wrong
This is a small pilot study, so results may not be conclusive. The procedure adds complexity to already intensive care, and it is unclear if removing CRP will meaningfully change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Heart Center Leipzig at University of Leipzig

    Leipzig, Saxony, 04289, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.